Home

Sarepta Therapeutics, Inc. - Common Stock (SRPT)

18.23
-0.58 (-3.08%)
NASDAQ · Last Trade: Nov 17th, 11:57 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close18.81
Open18.61
Bid18.22
Ask18.24
Day's Range18.01 - 18.70
52 Week Range10.42 - 138.81
Volume1,166,531
Market Cap1.70B
PE Ratio (TTM)-6.180
EPS (TTM)-3.0
Dividend & YieldN/A (N/A)
1 Month Average Volume6,014,465

Chart

About Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders. The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases. Read More

News & Press Releases

Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapystocktwits.com
FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.
Via Stocktwits · November 17, 2025
2 Beaten-Down Stocks to Avoid Right Nowfool.com
There might be plenty more downside for these biotechs.
Via The Motley Fool · November 15, 2025
Sarepta Shares Jump After FDA Approves Updated Elevidys Labelbenzinga.com
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.
Via Benzinga · November 14, 2025
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD).
By Sarepta Therapeutics, Inc. · Via Business Wire · November 14, 2025
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comebackstocktwits.com
Via Stocktwits · November 3, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · November 11, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · November 5, 2025
Analyst Ratings Send Ripples Through Markets: Sarepta's Resilience vs. Pinterest's Plunge
The financial markets are a complex ecosystem, constantly reacting to a myriad of inputs, from macroeconomic data to geopolitical shifts. Among the most closely watched catalysts are the pronouncements of influential Wall Street analysts. These upgrades, downgrades, and price target adjustments often act as immediate market movers, capable of sending
Via MarketMinute · November 5, 2025
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesdaybenzinga.com
Via Benzinga · November 5, 2025
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage clinical trial. The biopharmaceutical company revealed that its Phase 3 ESSENCE study, evaluating the efficacy of its Duchenne muscular dystrophy (DMD) therapies Amondys
Via MarketMinute · November 4, 2025
Which stocks are experiencing notable movement on Tuesday?chartmill.com
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Via Chartmill · November 4, 2025
Gold Falls Over 1%; Uber Shares Decline After Q3 Resultsbenzinga.com
Via Benzinga · November 4, 2025
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significancebenzinga.com
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.
Via Benzinga · November 4, 2025
Tuesday's session: top gainers and loserschartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · November 4, 2025
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes Itbenzinga.com
Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock.
Via Benzinga · November 4, 2025
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · November 4, 2025
These stocks are gapping in today's sessionchartmill.com
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · November 4, 2025
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
Tuesday's pre-market session: top gainers and loserschartmill.com
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · November 4, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watchstocktwits.com
While Dow Jones futures were down by 0.72% at the time of writing, the S&P 500 futures fell 1.02%.
Via Stocktwits · November 4, 2025
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 4, 2025
Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Whybenzinga.com
Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study.
Via Benzinga · November 3, 2025
These stocks are moving in today's after hours sessionchartmill.com
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 3, 2025
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Testsinvestors.com
Sarepta stock crashed Monday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.
Via Investor's Business Daily · November 3, 2025